NOTIFICATION OF TRADE AMONG PRIMARY INSIDERS

Reference is made to the stock exchange announcement from DiaGenic ASA (“DiaGenic” or the Company”) on 8 March 2013 regarding the conducted private placement in which the Company’s management and members of the board of directors have subscribed and been allocated shares at a subscription price of NOK 0.60 per share. The primary insiders have been allocated a total of 825,000 shares at NOK 0.60 per share. The transactions are described in more detail below.

Henrik Lund, Chairman of the Board of DiaGenic, was allotted 83,333 shares in the private placement. After the completion of the private placement Lund will increase his holding in the Company from 40,000 shares to 123,333 shares.

Patrik Dahlen, Deputy Chairman of the Board of DiaGenic, was allotted 250,000 shares in the private placement. After the completion of the private placement Dahlen will increase his holding in the Company from 0 shares to 250,000 shares.

Ingrid Wiik, Board member of DiaGenic, was allotted 125,000 shares in the private placement. After the completion of the private placement Wiik will increase her holding in the Company from 20,000 shares to 145,000 shares.

Tom Pike, Board member of DiaGenic, was allotted 100,000 shares in the private placement. After the completion of the private placement Pike will increase his holding in the Company from 0 shares to 100,000 shares.

Paul de Potocki, CEO in DiaGenic, was allotted 100,000 shares in the private placement. After the completion of the private placement Potocki will increase his holding in the Company from 0 shares and 1,000,000 share options, to 100,000 shares and 1,000,000 share options.

Magnus Sjögren, CMO in DiaGenic, was allotted 66,667 shares in the private placement. After the completion of the private placement Sjögren will increase his holding in the Company from 0 shares and 85,000 share options, to 66,667 shares and 85,000 share options.

Ruben Ekbråten, CFO in DiaGenic, was allotted 100,000 shares in the private placement. After the completion of the private placement Ekbråten will increase his holding in the Company from 1,199 shares and 85,000 share options, to 101,199 shares and 85,000 share options.

The completion of the subscriptions in the Private Placement will be conditional upon (i) all necessary corporate resolutions being validly made, including without limitation approval by an Extraordinary General Meeting of the Company expected to be held on or about 2 April 2013, and (ii) registration of the increased share capital of the Company pursuant to the private placement in the Norwegian Register of Business Enterprises.

Contact:

Paul de Potocki, Chief Executive Officer

Telephone: 47 2324 8950

e-mail: paul.depotocki@diagenic.com

About DiaGenic ASA

DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com